Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Completed · Phase 2

Conditions studied: Chronic Obstructive Pulmonary Disease

In brief

The primary objective of this study is to assess the efficacy of Glycopyrrolate/Formoterol Fumarate MDI relative to individual components (GP MDI and FF MDI) in subjects with moderate to severe COPD

Key facts

Study ID
NCT01587079
Run by
Pearl Therapeutics, Inc.
People needed
159
Starts
2012-04-01
Expected to finish
2012-10-01
Last updated by the study team
2016-06-30

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.